secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
CIK:        0001335105
Form:       8-K
Filed at:   2024-12-02T23:59:59+00:00
Accession:  0001493152-24-048292
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lixte pauses NKI/Oncode collaboration until Phase 1b trial starts; budget cut to €100K
--------------------------------------------------------------------------------

- Amendment 3 pauses research activities under the development collaboration with NKI and Oncode Institute.
- Collaboration resumes upon first patient dosing in Phase 1b trial combining LB-100 with a WEE1 inhibitor in metastatic colorectal cancer.
- Termination date revised to one year from first patient dosing; annual budget reduced from €250,000 to €100,000.
- Parties will study translational data from patient samples in NKI clinical trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1335105/000149315224048292/0001493152-24-048292-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1335105/000149315224048292/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-048292

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer